DBV Technologies S.A. logo
DBV Technologies S.A. DBVT
$ 21.59 -0.12%

Quarterly report 2025-Q2
added 07-29-2025

report update icon

DBV Technologies S.A. Income Statement 2011-2026 | DBVT

Annual Income Statement DBV Technologies S.A.

2024 2023 2022 2021 2020 2019 2018 2017 2016 2015 2014 2013 2012 2011

Market Cap

630 M 81.8 M 108 M 87.9 M 152 M 569 M 387 M 1.16 B 1.7 B 1.12 B 781 M - - -

Shares

97 M 95.1 M 77.4 M 54.9 M 57.8 M 57.8 M 57.8 M 49.5 M 48.9 M 43 M 32.2 M - - -

Historical Prices

6.5 0.86 1.39 1.6 2.62 10.7 6.42 24.6 35.1 36.3 27.1 - - -

Net Income

-114 M -72.7 M -96.3 M -97.8 M -160 M -154 M -166 M -148 M -115 M -44.7 M -24 M -19.3 M -13 M -7.24 M

Revenue

4.15 M 15.7 M 4.84 M 5.71 M - - - - - 202 K 211 K 182 K 174 K 126 K

Gross Profit

- - - - - - - - - 74 K 74.5 K 79.4 K 91.4 K 61 K

Operating Income

-117 M -76.4 M -96.6 M -98.6 M -159 M -171 M - - - - - - - -

EBITDA

-114 M -72.9 M -93.9 M -94.2 M -154 M -150 M -164 M -145 M -116 M -45.5 M -24.1 M -19.6 M -13.2 M -7.09 M

Operating Expenses

121 M 92.2 M 101 M 104 M 135 M 152 M 166 M 145 M 116 M 45.6 M 39 M 20 M 13.6 M 7.32 M

General and Administrative Expenses

28.7 M 29.5 M 24.3 M 30.5 M 40.1 M 56.4 M 52.2 M 42.4 M 39.8 M 16.9 M 8.12 M 6.31 M 4.62 M 2.39 M

All numbers in USD currency

Quarterly Income Statement DBV Technologies S.A.

2025-Q2 2025-Q1 2024-Q3 2024-Q2 2024-Q1 2023-Q3 2023-Q2 2023-Q1 2022-Q4 2022-Q3 2022-Q2 2022-Q1 2021-Q4 2021-Q3 2021-Q2 2021-Q1 2020-Q4 2020-Q3 2020-Q2 2020-Q1 2019-Q4 2019-Q3 2019-Q2 2019-Q1 2018-Q4 2018-Q3 2018-Q2 2018-Q1 2017-Q4 2017-Q3 2017-Q2 2017-Q1 2016-Q4 2016-Q3 2016-Q2 2016-Q1 2015-Q4 2015-Q3 2015-Q2 2015-Q1 2014-Q4 2014-Q3 2014-Q2 2014-Q1 2013-Q4 2013-Q3 2013-Q2 2013-Q1 2012-Q4 2012-Q3 2012-Q2 2012-Q1 2011-Q4 2011-Q3 2011-Q2 2011-Q1

Shares

134 M 103 M 96.2 M 96.2 M 96.2 M 96.1 M 94.3 M 94 M - 93.9 M 66 M 54.9 M - 54.9 M 54.9 M 54.9 M - 54.8 M 54.9 M 51.8 M - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - -

Net Income

-41.9 M -27.1 M -30.4 M -33.1 M -27.3 M -16.7 M -24.2 M -20.6 M - -17.3 M -23 M -16.7 M - -24 M -30.7 M -29.4 M - -31 M -48.2 M -40.9 M - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - -

Revenue

1.46 M 753 K 1.07 M 1.16 M 1.41 M 2.37 M 2.29 M 2.19 M - 2.07 M 1.53 M 2.55 M - 1.32 M -1.49 M 2.94 M - 4.16 M 3.61 M 4.72 M - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - -

Operating Income

-41.1 M -26.6 M -30.3 M -33.8 M -28.6 M -18.3 M -25.1 M -21.2 M - -18 M -23.8 M -16.8 M - -24.4 M -31.1 M -29.6 M - -29.8 M -47.7 M -41.2 M - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - -

EBITDA

- - - - - - - - - -18 M -23.8 M -16.8 M - -24.4 M -31.1 M -29.6 M - -29.8 M -47.7 M -41.2 M - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - -

Operating Expenses

42.6 M 27.4 M 31.4 M 35 M 30 M 20.6 M 27.4 M 23.4 M - 20.1 M 25.4 M 19.3 M - 25.7 M 29.6 M 32.6 M - 33.9 M 51.3 M 45.9 M - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - -

General and Administrative Expenses

8.46 M 5.63 M 7.22 M 8.64 M 7.8 M 6.18 M 9.23 M 6.89 M - 4.84 M 5.7 M 6.63 M - 8.3 M 8.27 M 9.68 M - 6.86 M 8.86 M 11.1 M - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - -

All numbers in USD currency

The income statement is one of the three key financial reports of a company DBV Technologies S.A. (alongside the balance sheet and the cash flow statement). It shows how the company makes money and what its expenses are:

  • How much revenue the company earned
  • How much it spent on production, personnel, marketing, taxes, etc.
  • What profit remained in the end

Analyzing the income statement helps an investor understand whether the business generates stable and growing profits, how effectively the company controls its expenses, and whether it is capable of generating income in the future. Additionally, this analysis shows how the company copes with crises and economic cycles, and allows assessing the potential for stock price growth and dividend payments.

Features
  • The income statement may include both recurring and one-time items (for example, profit from the sale of assets). It is necessary to separate core metrics from one-off events for accurate analysis.
  • Companies often publish interim reports (e.g., quarterly), which allows for more timely tracking of trends.
  • A combined analysis of the income statement with the balance sheet and cash flow statement provides a comprehensive view of the company’s financial health.

Reports on the profits and losses of other stocks in the Biotechnology industry

Issuer Price % 24h Market Cap Country
MorphoSys AG MorphoSys AG
MOR
- 2.43 % $ 254 M germanyGermany
ARCA biopharma ARCA biopharma
ABIO
- 1052.0 % $ 415 M usaUSA
Adaptive Biotechnologies Corporation Adaptive Biotechnologies Corporation
ADPT
$ 18.33 -0.92 % $ 2.7 B usaUSA
Amgen Amgen
AMGN
$ 343.48 0.47 % $ 184 B usaUSA
Arrowhead Pharmaceuticals Arrowhead Pharmaceuticals
ARWR
$ 72.81 5.02 % $ 9.74 B usaUSA
I-Mab I-Mab
IMAB
- - $ 866 M chinaChina
Aytu BioScience Aytu BioScience
AYTU
$ 2.72 4.62 % $ 17.1 M usaUSA
Alexion Pharmaceuticals, Inc. Alexion Pharmaceuticals, Inc.
ALXN
- - $ 40.3 B usaUSA
Adagene Adagene
ADAG
$ 2.99 8.55 % $ 168 M chinaChina
Biogen Biogen
BIIB
$ 177.96 -1.07 % $ 25.9 B usaUSA
Biophytis SA Biophytis SA
BPTS
- -13.47 % $ 169 M franceFrance
Midatech Pharma plc Midatech Pharma plc
MTP
- -18.52 % $ 27.3 M britainBritain
EyeGate Pharmaceuticals, Inc. EyeGate Pharmaceuticals, Inc.
EYEG
- -1.52 % $ 24.7 M usaUSA
Akero Therapeutics Akero Therapeutics
AKRO
- - $ 3.67 B usaUSA
Alterity Therapeutics Limited Alterity Therapeutics Limited
ATHE
$ 3.12 -1.74 % $ 7.51 B australiaAustralia
Acorda Therapeutics Acorda Therapeutics
ACOR
- -24.86 % $ 820 K usaUSA
Aptose Biosciences Aptose Biosciences
APTO
- -45.71 % $ 1.2 M canadaCanada
Acasti Pharma Acasti Pharma
ACST
- 4.01 % $ 150 M canadaCanada
Aeglea BioTherapeutics Aeglea BioTherapeutics
AGLE
- - $ 1.01 B usaUSA
Akebia Therapeutics Akebia Therapeutics
AKBA
$ 1.4 -0.71 % $ 262 M usaUSA
Albireo Pharma Albireo Pharma
ALBO
- -0.23 % $ 916 M usaUSA
Институт стволовых клеток человека Институт стволовых клеток человека
ISKJ
- - - russiaRussia
Allena Pharmaceuticals Allena Pharmaceuticals
ALNA
- 3.16 % $ 1.9 M usaUSA
Ascendis Pharma A/S Ascendis Pharma A/S
ASND
$ 223.74 -1.05 % $ 5 B danmarkDanmark
Ampio Pharmaceuticals Ampio Pharmaceuticals
AMPE
- -11.43 % $ 502 K usaUSA
Burford Capital Limited Burford Capital Limited
BUR
$ 9.85 1.65 % $ 1.59 B britainBritain
Applied Molecular Transport Applied Molecular Transport
AMTI
- - $ 10.1 M usaUSA
Can-Fite BioPharma Ltd. Can-Fite BioPharma Ltd.
CANF
$ 4.13 2.92 % $ 8.99 B israelIsrael
Aravive Aravive
ARAV
- -13.39 % $ 1.45 M usaUSA
BioNTech SE BioNTech SE
BNTX
$ 110.82 -2.58 % $ 27.2 B germanyGermany
Athira Pharma Athira Pharma
ATHA
- - $ 269 M usaUSA
Aeterna Zentaris Aeterna Zentaris
AEZS
- 5.93 % $ 314 M canadaCanada
Autolus Therapeutics plc Autolus Therapeutics plc
AUTL
$ 1.39 1.09 % $ 355 M britainBritain
AgeX Therapeutics AgeX Therapeutics
AGE
- -10.17 % $ 12.2 K usaUSA
AVROBIO AVROBIO
AVRO
- 1083.1 % $ 745 M usaUSA
Cardiff Oncology Cardiff Oncology
CRDF
$ 1.72 -2.0 % $ 82 M usaUSA
Akouos Akouos
AKUS
- 0.23 % $ 488 M usaUSA
Adaptimmune Therapeutics plc Adaptimmune Therapeutics plc
ADAP
- -15.15 % $ 60.3 M britainBritain
Brickell Biotech Brickell Biotech
BBI
- -5.38 % $ 6.06 M usaUSA
Amneal Pharmaceuticals Amneal Pharmaceuticals
AMRX
$ 14.17 3.55 % $ 4.38 B usaUSA
Compugen Ltd. Compugen Ltd.
CGEN
$ 1.85 0.27 % $ 166 M israelIsrael
AIkido Pharma AIkido Pharma
AIKI
- 1.93 % $ 17.4 M usaUSA
Atreca Atreca
BCEL
- -11.76 % $ 5.79 M usaUSA
CureVac N.V. CureVac N.V.
CVAC
- - $ 867 M germanyGermany
Acer Therapeutics Acer Therapeutics
ACER
- 2.71 % $ 14 M usaUSA
BioCryst Pharmaceuticals BioCryst Pharmaceuticals
BCRX
$ 6.68 1.52 % $ 1.38 B usaUSA
Alpine Immune Sciences Alpine Immune Sciences
ALPN
- - $ 2.17 B usaUSA
AlloVir AlloVir
ALVR
- 4.14 % $ 49.1 M usaUSA
Beam Therapeutics Beam Therapeutics
BEAM
$ 28.17 1.99 % $ 2.32 B usaUSA
BeiGene, Ltd. BeiGene, Ltd.
BGNE
- 0.49 % $ 251 B cayman-islandsCayman-islands